XORTX THERAPEUTICS INC (XRTX)

CA98420Q3061 - Common Stock

2.56  +0.01 (+0.39%)

Fundamental Rating

2

XRTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for XRTX as it has an excellent financial health rating, but there are worries on the profitability. XRTX does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

XRTX had negative earnings in the past year.
In the past year XRTX has reported a negative cash flow from operations.
XRTX had negative earnings in each of the past 5 years.
In the past 5 years XRTX always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of XRTX (-39.47%) is comparable to the rest of the industry.
XRTX's Return On Equity of -46.49% is in line compared to the rest of the industry. XRTX outperforms 58.46% of its industry peers.
Industry RankSector Rank
ROA -39.47%
ROE -46.49%
ROIC N/A
ROA(3y)-36.45%
ROA(5y)-44.66%
ROE(3y)-55.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

XRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, XRTX has more shares outstanding
XRTX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for XRTX has been reduced compared to a year ago.

2.2 Solvency

XRTX has an Altman-Z score of -2.29. This is a bad value and indicates that XRTX is not financially healthy and even has some risk of bankruptcy.
XRTX has a Altman-Z score of -2.29. This is comparable to the rest of the industry: XRTX outperforms 44.62% of its industry peers.
There is no outstanding debt for XRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.29
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

XRTX has a Current Ratio of 13.80. This indicates that XRTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of XRTX (13.80) is better than 89.74% of its industry peers.
A Quick Ratio of 13.80 indicates that XRTX has no problem at all paying its short term obligations.
XRTX has a Quick ratio of 13.80. This is amongst the best in the industry. XRTX outperforms 90.26% of its industry peers.
Industry RankSector Rank
Current Ratio 13.8
Quick Ratio 13.8

0

3. Growth

3.1 Past

The earnings per share for XRTX have decreased strongly by -78.04% in the last year.
EPS 1Y (TTM)-78.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q996.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

XRTX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.31%
EPS Next 2Y-4.43%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as XRTX's earnings are expected to decrease with -4.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.43%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

XRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

XORTX THERAPEUTICS INC

NASDAQ:XRTX (5/1/2024, 6:33:11 PM)

2.56

+0.01 (+0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.12M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.47%
ROE -46.49%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 13.8
Quick Ratio 13.8
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-78.04%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y